IDHIFA: payments to doctors
Payments that named IDHIFA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $180K
- Providers
- 2,061
- Transactions
- 3,328
- Average per transaction
- $54
The per-transaction average — $54 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,061 providers the average total is $87, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bristol Myers Squibb | $86,012 | 47.9% |
| Agios Pharmaceuticals, Inc. | $60,417 | 33.6% |
| Servier Pharmaceuticals LLC | $33,184 | 18.5% |
| E.r. Squibb & Sons, L.L.C. | $26 | 0.0% |